Abstract |
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF(V600)-mutant melanoma but activates extracellular signal-regulated kinase (ERK) signaling in RAS-mutant cells. In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia. We hypothesized that combining vemurafenib with a MAP-ERK kinase ( MEK) inhibitor would inhibit ERK activation in the melanoma and prevent ERK activation by vemurafenib in the leukemia, and thus suppress both malignancies. We demonstrate that intermittent administration of vemurafenib led to a near-complete remission of the melanoma, and the addition of the MEK inhibitor cobimetinib (GDC-0973) caused suppression of vemurafenib-induced leukemic proliferation and ERK activation. Antimelanoma and antileukemia responses have been maintained for nearly 20 months, as documented by serial measurements of tumor-derived DNA in plasma in addition to conventional radiographic and clinical assessments of response. These data support testing of intermittent ERK pathway inhibition in the therapy for both RAS-mutant leukemia and BRAF-mutant melanoma.
|
Authors | Omar Abdel-Wahab, Virginia M Klimek, Alisa A Gaskell, Agnes Viale, Donavan Cheng, Eunhee Kim, Raajit Rampal, Mark Bluth, James J Harding, Margaret K Callahan, Taha Merghoub, Michael F Berger, David B Solit, Neal Rosen, Ross L Levine, Paul B Chapman |
Journal | Cancer discovery
(Cancer Discov)
Vol. 4
Issue 5
Pg. 538-45
(May 2014)
ISSN: 2159-8290 [Electronic] United States |
PMID | 24589925
(Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Azetidines
- DNA, Neoplasm
- Indoles
- Membrane Proteins
- Piperidines
- Sulfonamides
- Vemurafenib
- BRAF protein, human
- Proto-Oncogene Proteins B-raf
- GTP Phosphohydrolases
- NRAS protein, human
- cobimetinib
|
Topics |
- Aged
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Azetidines
(administration & dosage, therapeutic use)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- DNA, Neoplasm
(analysis)
- Drug Administration Schedule
- GTP Phosphohydrolases
(antagonists & inhibitors, genetics)
- Humans
- Indoles
(administration & dosage, therapeutic use)
- Leukemia
(chemically induced, prevention & control)
- MAP Kinase Signaling System
(drug effects)
- Male
- Melanoma
(drug therapy, genetics, pathology)
- Membrane Proteins
(antagonists & inhibitors, genetics)
- Mutation
- Neoplastic Cells, Circulating
(drug effects)
- Piperidines
(administration & dosage, therapeutic use)
- Proto-Oncogene Proteins B-raf
(antagonists & inhibitors, genetics)
- Sulfonamides
(administration & dosage, therapeutic use)
- Vemurafenib
|